Defense 5 Companies Earnings Outlook: Is H2 Order Momentum Valid? | Park Se-ik Executive Director & Chesley Investment Advisory [Morning Brief Highlight]

Summary

Choi Ho and Park Se-ik review the Q2 earnings preview and H2 order outlook for five major Korean defense companies, highlighting a sector-wide re-rating opportunity driven by upcoming contract catalysts and rotational flows. They single out LIG Nex1 as a top pick due to its long order backlog and air defense demand. The discussion also covers Pharma Research's export-led growth story, with a buying opportunity ahead of its Q2 report. Brief semiconductor commentary suggests patience amid market noise.

• Korean defense stocks have underperformed but H2 order catalysts (K9, K2, Chunmoo) may drive re-rating and sector rotation.
• LIG Nex1 is favored for its Q2 earnings beat, 5-year order backlog, and strong missile defense demand.
• Hyundai Rotem and other defense names missed Q2 expectations but valuations have become cheaper after recent pullbacks.
• Pharma Research is pivoting to export-driven growth via medical devices and cosmetics, helped by a US manufacturing acquisition.
• Pharma Research's Q2 margin recovery to 40% and recent stock support suggest a dip-buying opportunity into the August earnings.
• Semiconductor market noise from CoreWeave hedging news and CXMT listing keeps a wait-and-see stance.
• The hosts emphasize a disciplined rotation strategy—buying quality stocks on pullbacks rather than chasing rallies.